Flag of the European Union EU Clinical Trials Register Help

Clinical trials for remdesivir

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43861   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: remdesivir. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-001453-49 Sponsor Protocol Number: GS-US-540-5821 Start Date*: 2020-04-10
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Expanded Access Treatment Protocol: Remdesivir (RDV;GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection- COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002275-34 Sponsor Protocol Number: WA42511 Start Date*: 2020-11-13
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REMDESIVIR PLUS TOCILIZUMAB COMPARED WITH REMDESIVIR PLUS PLACEBO IN HOSPITALIZED PATIENTS WITH SEVER...
    Medical condition: Severe coronavirus disease 2019 (COVID-19) pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000841-15 Sponsor Protocol Number: GS-US-540-5773 Start Date*: 2020-03-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Completed) NL (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000842-32 Sponsor Protocol Number: GS-US-540-5774 Start Date*: 2020-03-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Completed) NL (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000982-18 Sponsor Protocol Number: NOR-SOLIDARITY Start Date*: 2020-03-26
    Sponsor Name:Oslo University Hospital
    Full Title: The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19).
    Medical condition: SARS-COV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10037373 Pulmonary disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001803-17 Sponsor Protocol Number: GS-US-540-5823 Start Date*: 2020-07-14
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004928-42 Sponsor Protocol Number: REM-ENY-01 Start Date*: 2020-10-12
    Sponsor Name:Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium
    Full Title: Open-label study to assess the safety of REMdesivir-HU as Eligible Novel therapY for moderate and severe Covid-19 patients
    Medical condition: SARS-CoV-2 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001366-11 Sponsor Protocol Number: Solidarity Start Date*: 2020-03-27
    Sponsor Name:FIB-HCSC [...]
    1. FIB-HCSC
    2. WHO (World Health Organization)
    Full Title: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) LT (Ongoing) IE (Completed) IT (Ongoing) PT (Temporarily Halted) SK (Ongoing) RO (Ongoing) LV (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2020-003510-12 Sponsor Protocol Number: GS-US-540-9012 Start Date*: 2020-10-02
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) PT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005416-22 Sponsor Protocol Number: GS-US-540-5912 Start Date*: 2021-03-24
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who ...
    Medical condition: Coronavirus disease 2019 (COVID-19) in patients with chronic renal impairment
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004695-18 Sponsor Protocol Number: RES-Q-HR Start Date*: 2020-12-02
    Sponsor Name:Heinrich-Heine-University Düsseldorf
    Full Title: Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals
    Medical condition: The novel coronavirus designated SARS CoV-2, and the disease caused by this virus designated COVID-19. No treatment is available for early disease stages and non-hospitalized patients to date. This...
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 100000004848 10084442 SARS-CoV-2 PCR test positive LLT
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002060-31 Sponsor Protocol Number: WHOCOVID-19coreprotocol Start Date*: 2020-06-22
    Sponsor Name:Masaryk University
    Full Title: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001549-38 Sponsor Protocol Number: WHO-SOLIDARITY-GERMANY Start Date*: 2020-06-29
    Sponsor Name:Gesundheit Nord gGmbH
    Full Title: An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10037373 Pulmonary disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001052-18 Sponsor Protocol Number: 010 Start Date*: 2020-03-25
    Sponsor Name:Regents of the University of Minnesota
    Full Title: A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European U...
    Medical condition: Influenza COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) DE (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-001457-43 Sponsor Protocol Number: APHP200388 Start Date*: 2020-04-10
    Sponsor Name:APHP
    Full Title: Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia
    Medical condition: acute hypoxemic respiratory failure (AHRF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005951-19 Sponsor Protocol Number: APL-D-003-20 Start Date*: 2021-06-08
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patients Requiring Hospitalisation for Management...
    Medical condition: moderate COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BG (Prematurely Ended) GR (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005849-16 Sponsor Protocol Number: KIN001-203 Start Date*: 2021-03-09
    Sponsor Name:Kinarus AG
    Full Title: An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patient...
    Medical condition: COVID-19 development in hospitalized patients infected with SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003278-37 Sponsor Protocol Number: INSIGHT-014-ACTIV-3 Start Date*: 2020-09-04
    Sponsor Name:Regents of the University of Minesota
    Full Title: A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19
    Medical condition: Subjects infected with SARS-CoV-2, admitted to the hospital due to COVID-19.
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) SE (Prematurely Ended) PL (Completed) GR (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001302-30 Sponsor Protocol Number: ACOVACT Start Date*: 2020-04-15
    Sponsor Name:Medical University of Vienna
    Full Title: A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute re...
    Medical condition: Infection with SARS-COV-2 (=COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035737 Pneumonia viral PT
    21.1 100000004855 10003083 ARDS LLT
    20.0 10021881 - Infections and infestations 10038700 Respiratory infection LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005919-51 Sponsor Protocol Number: REP0220 Start Date*: 2021-01-19
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A phase 3, double-blind, randomized, placebo-controlled, multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with severe COVID-19 pneumonia.
    Medical condition: COVID-19 Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 03:20:24 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA